All Categories
Optimisation immunotherapy clinical trials investigate ways of reducing the intensity of immunotherapy cancer treatment. This could be beneficial for patients’ quality of life. But these trials can be challenging to run, as patients may be concerned about the impact that reducing the intensity of treatment could have on the cancer.
This episode of the Trial Talk podcast focuses on the MRC Clinical Trials Unit at UCL’s OPTIC study, which explores how people with cancer feel about taking part in optimisation immunotherapy trials. Clinical Fellow Sophie Merrick discusses the main barriers that patients face and recommendations to address them.
Resources:
•OPTIC study page: www.mrcctu.ucl.ac.uk/studies/all-st…/refine/optic/
•OPTIC results paper: www.nature.com/articles/s41416-024-02756-x.pdf
•REFINE podcast episode: on.soundcloud.com/Fe3C76csHkgCg2or5
For questions or feedback on the series, message us at mrcctu.engage@ucl.ac.uk
For more information and to access the transcript: bit.ly
0
6/18/2024
UCL Computational Cancer Collaboratorium Seminar Series
"Fluctuating DNA methylation for lineage tracing in healthy human tissues and Cancer"
Speaker: Professor Trevor Graham, FMedSci Director, Centre for Evolution and Cancer Institute of Cancer Research, London
Date: Tuesday 12 December 2023
17
12/19/2023
STAMPEDE is a long-running trial in advanced prostate cancer, in which nearly 12,000 men have taken part. Thanks to its multi-arm multi-stage platform design, STAMPEDE has tested many different treatments and directly led to improvements in the standard of prostate cancer care several times.
This Trial Talk podcast mini-series will explore the trial’s journey from its inception in the early 2000s to the end of patient recruitment in March 2023.
In the final part, Max Parmar and Nick James look back over the trial’s impact on clinical practice and platform trial design, and look forward to STAMPEDE2 and their hopes for the future of prostate cancer research.
-
Further information is available on the STAMPEDE study page at www.mrcctu.ac.uk
For questions or feedback on the series, message us at mrcctu.engage@ucl.ac.uk
For more information and to access the transcript: bit.ly/3OQWhV8
As a listener, your opinion is very valuable to us. Please help us to improve the podcast in future
6
8/23/2023
Immunotherapy drugs fight cancer by helping the immune system recognise and attack cancer cells. These drugs have revolutionised cancer treatment over the last decade, improving survival for many people with different types of cancer.
However, researchers are still unsure of the best way to give immunotherapy, which can come with unpredictable side effects.
In this episode, Clinical Fellow Sophie Merrick discusses how the REFINE trial hopes to address this problem, by testing if giving immunotherapy less frequently can still treat the cancer effectively, whilst improving the quality of life for patients, reducing side effects and costs.
Further information is available on the REFINE study page at www.mrcctu.ac.uk
For questions or feedback on the series, message us at mrcctu.engage@ucl.ac.uk
For more information and to access the transcript: https://bit.ly/3DgIDE2
0
7/18/2023
Reconstructing a face after cancer surgery - (video)
UCL Vintage Podcasts
3
7/5/2023
In this first episode, we talk to Dr Ajay Aggarwal about an exciting new study to evaluate if artificial intelligence (AI) can transform the way we plan radiotherapy in low- and middle-income countries (LMIC). The study is called the ARCHERY (short for “Artificial Intelligence based radiotherapy treatment planning for Cervical, Head and Neck and Prostate cancer”).
Ajay explains how this study could improve global access to radiotherapy by automatising parts of radiotherapy treatment planning using AI. He also highlights the importance of evaluating the implementation and cost-effectiveness of this AI approach, as well as its plan to build capacity in LMIC.
60
11/8/2022
The AdReNa (Adaptive and Responsive Nanomaterials) research group is interested in the fundamental question of how materials form and interact on the nanoscale with the aim to create colloids and interfaces that can selectively interact with chemical and biological targets. In this talk, Stefan Guldin will show how this research is relevant for applications in healthcare and the environment, in particular how our work at UCL informs clinical prototypes for therapeutic drug monitoring in paediatric cancer.
2
8/17/2022
Scientists at UCL have developed a novel cancer therapy that uses an MRI scanner to guide a magnetic seed through the brain to heat and destroy tumours.
11
2/4/2022